First in Human Study of AZD9592 in Solid Tumors

Key Inclusion Criteria:

• Age ≥ 18 years

• Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1

• Life expectancy ≥ 12 weeks

• Measurable disease per RECIST v1.1

• Adequate organ and marrow function as defined in the protocol

Additional Inclusion Criteria for Module 1:

• Histologically or cytologically confirmed metastatic or locally advanced EGFRmut., NSCLC; metastatic EGFRwt. NSCLC; recurrent or metastatic HNSCC of the oral cavity; metastatic CRC.

Additional Inclusion Criteria for Module 2:

• Histologically or cytologically confirmed metastatic NSCLC EGFRmut.

Additional Inclusion Criteria for Module 3:

• Histologically or cytologically confirmed metastatic CRC.

Key Exclusion Criteria:

• History of (non-infectious) ILD/pneumonitis that required steroids, has currentILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imagingat screening.

• Spinal cord compression or a history of leptomeningeal carcinomatosis.

• Active infection including tuberculosis and HBV, HCV or HIV

• Brain metastases unless treated (prior treatment required only for Module 1),asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10mg prednisone/day or equivalent for at least 4 weeks prior to start of studytreatment.

• Participants with cardiac comorbidities as defined in the study protocol